Why the study?
Cardiovascular or pulmonary involvement occurs in child-onset SLE, but myocarditis and pulmonary hypertension are infrequent and can be life-threatening.
Does aggressive immunosuppressive therapy improve outcomes in pediatric SLE presenting with severe myocarditis or pulmonary hypertension?
Does aggressive immunosuppressive therapy improve outcomes in pediatric SLE presenting with severe myocarditis or pulmonary hypertension?
Aggressive immunosuppressive therapy can lead to favorable long-term outcomes in pediatric SLE patients presenting with severe cardiovascular complications like myocarditis and pulmonary hypertension.
Rare pediatric SLE cardiac presentation warrants vigilance; hypothesis-generating and leaves open optimal management strategies.
Systemic lupus erythematosus (SLE) is an autoimmune disease that may cause vital organ damage. Although not rare for child-onset SLE to have cardiovascular or pulmonary involvement, myocarditis, and pulmonary hypertension are infrequent features and can be life-threatening. In this case report, we describe an 11-year-old girl with SLE who initially presented with fulminant myocarditis pulmonary hypertension, and massive pericardial effusion. Initial immunosuppressive therapy with methylprednisolone pulse therapy, and IVIG were administered, followed by cyclophosphamide, which was ultimately successful, with no residual pulmonary hypertension and no recurrence of myocarditis for over 3 years after the initial episode. Our case highlights the need for clinicians to be aware of systemic lupus erythematosus as a possible diagnostic entity in pediatric patients with severe myocarditis or pulmonary hypertension. Aggressive immunosuppressive therapy should be strongly considered in such cases, as it may lead to good short-term and long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: